Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9201090 | 0.84 | HTT (0.39) | HTTCISD2LMNASMN1; SMN2NOTUM | |
| SCHEMBL9203467 | 0.77 | HTT (0.46) | HTTSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL1567868 | 0.74 | SMN1; SMN2 (0.44) | HTTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL9206182 | 0.72 | GAA (0.48) | LMNACYP2C19NPSR1 | |
| SCHEMBL9199991 | 0.71 | HTT (0.54) | HTTLMNASMN1; SMN2NOTUMNPSR1 | |
| SCHEMBL9200628 | 0.68 | HTT (0.54) | HTTLMNASMN1; SMN2CYP2C19NPSR1 | |
| SCHEMBL15983841 | 0.68 | HTT (0.44) | HTTLMNASMN1; SMN2 | |
| SCHEMBL9200259 | 0.67 | HTT (0.49) | HTTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL9203282 | 0.67 | ALOX15 (0.52) | HTTLMNASMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL9205844 | 0.67 | HTT (0.49) | HTTLMNASMN1; SMN2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119332-A1 | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) | JEPPESEN LONE (DK) | 2005-06-02 | — | — | US | disclosed |
| US-20020165398-A1 | Modulators of protein tyrosine phosphatases (PTPases) | JEPPESEN LONE (DK) | 2002-11-07 | — | — | US | disclosed |
| US-20020002199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | US | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1062204-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046244-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165398-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRO | HTT 563/4885GPR35 1740/4885CISD2 4652/4885 |
| US-20020002199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | PTPRCAP, PTPRS, PTPRA | HTT 511/4885GPR35 1716/4885CISD2 4661/4885 |
| US-20050119332-A1 | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPN1 | HTT 734/4885GPR35 1492/4885CISD2 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.